



**FOR IMMEDIATE RELEASE**

**CONTACT:** Tom Pearson (Investors)  
(617) 621-2345

Andrea Johnston (Media)  
Pure Communications  
(910) 681-1088

**ARIAD TO WEBCAST CONFERENCE CALL ON FIRST  
QUARTER 2005 FINANCIAL RESULTS**

**Cambridge, MA, April 27, 2005** – ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) will hold a live webcast of its quarterly conference call at 8:30 a.m. (ET) on Wednesday, May 4, 2005. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call. Senior management will discuss the Company's first-quarter financial results for 2005, progress towards 2005 goals including the designation of AP23573 as a fast-track product by the FDA, and additional corporate activities. The Company will announce the highlights of these topics in a press release to be issued before the market opens on May 4, 2005 prior to the conference call.

The live webcast can be accessed by visiting the investor relations section of the Company's website at <http://ariad.com/investor>. The call can be accessed by dialing 866-800-8649 (domestic) or 617-614-2703 (international) five minutes prior to the start time and providing the passcode 12991095. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for two weeks.

**About ARIAD**

ARIAD is engaged in the discovery and development of breakthrough medicines to treat disease by regulating cell signaling with small molecules. The Company is developing a comprehensive approach to patients with cancer that addresses the greatest medical need – aggressive and advanced-stage cancers for which current treatments are inadequate. Medinol Ltd. also is developing stents and other medical devices that deliver ARIAD's lead cancer product candidate to prevent reblockage at sites of vascular injury following stent-assisted angioplasty. ARIAD has an exclusive license to pioneering technology and patents related to certain NF- $\kappa$ B treatment methods, and the discovery and development of drugs to regulate NF- $\kappa$ B cell-signaling activity, which may be useful in treating certain diseases. Additional information about ARIAD can be found on the web at <http://www.ariad.com>.

Some of the matters discussed herein are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are identified by the use of words such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance. Such statements are based on management’s current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements. These risks include, but are not limited to, risks and uncertainties regarding the Company’s ability to accurately estimate the timing and actual research and development expenses and other costs associated with the preclinical and clinical development and manufacture of our product candidates, the adequacy of our capital resources and the availability of additional funding, risks and uncertainties regarding our ability to manufacture our product candidates on a commercial scale or to supply our product candidates to our collaborator for use in its product candidates, risks and uncertainties regarding our and our collaborator’s ability to successfully enroll and conduct preclinical and clinical studies of product candidates, including our product candidates to treat cancers described in this release and our collaborator’s medical device product candidates to treat vascular disease, risks and uncertainties that clinical trial results at any phase of development including those described in this release may be adverse or may not be predictive of future results or lead to regulatory approval of any of our or our collaborator’s product candidates, risks and uncertainties of third-party intellectual property claims relating to our and our collaborator’s product candidates, and risks and uncertainties relating to regulatory oversight, the timing, scope, cost and outcome of legal proceedings, including litigation concerning our NF-κB patent portfolio, future capital needs, key employees, dependence on our collaborators and manufacturers, markets, economic conditions, products, services, prices, reimbursement rates, competition and other risks detailed in the Company’s public filings with the Securities and Exchange Commission, including ARIAD’s Annual Report on Form 10-K for the fiscal year ended December 31, 2004. The information contained in this document is believed to be current as of the date of original issue. The Company does not intend to update any of the forward-looking statements after the date of this document to conform these statements to actual results or to changes in the Company’s expectations, except as required by law.

###